Navigation Links
R-Tech Ueno Starts Early Phase II Clinical Trial for RK-023
Date:10/6/2009

TOKYO, Oct. 6 /PRNewswire/ -- R-Tech Ueno, Ltd. has started early Phase II clinical trial for RK-023, a physiologically active fatty acid derivative developed by the company -- a new compound targeted as a treatment for androgenetic alopecia (male pattern baldness) (Note 1).

Phase I clinical trial in healthy male volunteers that began in 2008 demonstrated the safety of RK-023 (Note 2). Early phase II clinical trial has been started for two purposes. One is to evaluate the safety of RK-023 for long-term use by men with pattern baldness. The other is to examine the preliminary effectiveness of this compound on hair growing. This clinical trial will be a double blind (Note 3), placebo-controlled (Note 4) study in which the study drug is applied to the scalp for 13 consecutive weeks.

"I am very pleased that early phase II clinical trial for RK-023 has started," said Dr. Yukihiko Mashima, president of R-Tech Ueno. "This is a compound that we are developing on our own for the treatment of male pattern baldness, which is part of our core dermatology operations. We plan to proceed with development activities quickly while conducting negotiations concerning alliances with companies in Japan and overseas."

R-Tech Ueno determines to complete the development of RK-023, quickly in order to provide assistance as soon as possible to men who are troubled by the loss of hair.

Notes:

  1. Androgenetic alopecia (male pattern baldness) is also called common baldness with aging. Following puberty, male hormones can prevent the regeneration of thick, long hair starting at the top of the skull and spreading forward. This hair is gradually replaced with thin, short hair. Eventually, this process leads to the atrophy of hair follicles and a decline in the number of strands of hair. Men first experience thinning of their hair and then baldness. This condition affects about 12 million men in Japan.
  2. See the R-Tech Ueno pres
    '/>"/>

SOURCE R-Tech Ueno, Ltd.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. R-Tech Ueno, Ltd. Completes Phase 1 Clinical Study on RK-023
2. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
3. New Company Starts, Bridging the Development Gap in the Discovery of Cancer Drugs
4. VIDEO: Femara(R) helps protect against return of breast cancer even when treatment starts several years after completing tamoxifen therapy
5. Impliant Restarts Pivotal Clinical Trial for Patented TOPS(TM) Spine System
6. BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
7. U.S. NCI Starts Enrolment in Phase 2 Systemic Melanoma Clinical Trial with REOLYSIN(R)
8. Presbyterian Hospital Dallas Starts Advanced Breast-Cancer Risk-Assessment Program
9. Clinical Update - Debio 9902 SR (ZT-1) for Alzheimer Patients Debiopharm Starts Tablet Formulations Bridging Study under IND
10. Sanofi Pasteur Starts a Phase II Study of a Vaccine Against Clostridium Difficile
11. GeoVax Starts Injections for Phase 2a Human HIV/AIDS Vaccine Trial in USA
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/22/2014)... 22, 2014 BiologicTx ® today announced ... 3-way Kidney Paired Donation transplant exchange utilizing BiologicTx,s proprietary ... July 9 at the Miami Transplant Institute, located at ... Kidney Paired Donation (KPD) is ... for kidney transplant with one another due to incompatible ...
(Date:7/22/2014)...  A central New York ... Total Artificial Heart implant is home, discharged from ... Freedom® portable driver to wait for a matching ... from a Syracuse architectural hardware company, suffered from ... medications, an implantable defibrillator and a pacemaker. ...
(Date:7/22/2014)... -- Halozyme Therapeutics, Inc. (NASDAQ: HALO ) today ... patients in its ongoing Phase 2 trial (Study 202) ... revised clinical protocol agreed to with the FDA in ... proprietary recombinant human hyaluronidase under development for the systemic ... "Our diligent effort to rapidly re-initiate patient enrollment and ...
Breaking Medicine Technology:BiologicTx Paired Donation Aids In Successful Kidney Transplants 2BiologicTx Paired Donation Aids In Successful Kidney Transplants 3'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 2'I'm a Heartless SOB' Jokes Patient Discharged from Strong Memorial Hospital without a Human Heart 3Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 2Halozyme Resumes Patient Enrollment And Dosing In PEGPH20 Clinical Program In Pancreatic Cancer 3
... RIDGEFIELD, Conn., Oct. 24, 2011 Apelon, ... data interoperability solutions, today announced the availability ... solution. TermManager, a code set management and ... interoperability initiatives by enabling widespread access to ...
... Codexis, Inc. (Nasdaq: CDXS ) ... Codex® Screening Kits are in use or evaluation ... worldwide.  The announcement was made at CPhI  Worldwide, ... week.   Codex® Screening Kits were ...
Cached Medicine Technology:Apelon Announces Availability of New TermManager® Software 250 Pharma Companies Worldwide Now Use Codexis In Process Development 2
(Date:7/22/2014)... Beach, FL (PRWEB) July 22, 2014 ... that they are now an authorized Daikin comfort pro ... and install Daikin indoor heating and cooling system equipment. ... each one is thoroughly reviewed before being approved. , ... an innovator in the Split System Air Conditioning Market. ...
(Date:7/22/2014)... 22, 2014 The 2014 Warrior-Family ... Ronald Reagan Building and International Trade Center in ... Families and Civilian Communities,” will be held from ... 7:30 a.m.) and cohosted by the Military Officers ... Industrial Association (NDIA). USAA is the Executive Sponsor ...
(Date:7/22/2014)... New York, NY (PRWEB) July 22, 2014 ... ( http://www.xareltolawsuitcenter.com/ ) that alleges the death ... bleeding caused by the blood thinner, Bernstein Liebhard LLP ... the U.S. District Court for the Southern District ... Xarelto in January 2012, and suffered a subdural hemorrhage ...
(Date:7/22/2014)... American Society of Hematology (ASH) will honor Tomas Ganz, ... Angeles with the 2014 E. Donnall Thomas Lecture for ... of the iron-regulatory hormone hepcidin and investigation of its ... Nobel Prize Laureate and past Society president E. Donnall ... have represented a paradigm shift or significant discovery in ...
(Date:7/22/2014)... of the Clean Plate Club you eat pretty much ... A new Cornell University study shows that the average ... his or her plate. "If you put it ... Wansink Ph.D., author of the forthcoming book, Slim by Design, ... Brand Lab. , Wansink and co-author Katherine Abowd Johnson analyzed ...
Breaking Medicine News(10 mins):Health News:Air Conditioning & Heating Inc. Now an Authorized Daikin Comfort Pro Dealer 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 2Health News:2014 Warrior-Family Symposium Focuses on Transitioning Forward 3Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 2Health News:Xarelto Lawsuit Filed by Florida Woman Alleges Uncontrollable Bleeding Led to Husband’s Death, Bernstein Liebhard LLP Reports 3Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 2Health News:Tomas Ganz, M.D., Ph.D., to present 2014 ASH E. Donnall Thomas Lecture 3
... babies of mother's with hypothyroidism are likely to ... hormones which control metabolism, growth and development. Symptoms ... ,Children born with an underactive thyroid ... the condition are more prone to a potentially ...
... supplements are often used by body builders, and there's some ... maintain muscle in older people? One new study indicates the ... 33 men aged 60 to 84 who had similar lifestyles ... training program. Half were given creatine and half were given ...
... not likely to get prostate cancer than men with other ... your blood group affects your health.// In particular, men with ... develop prostate cancer and to get more aggressive forms of ... men who have type A, but not confirmed as yet. ...
... bowel cancer. Research carried out by doctors at Oxford University ... that it reacts with acid in the stomach to prevent ... studied bowel cancer rates in 28 countries across the world, ... disease in the UK, the USA, Brazil, Colombia, Canada and ...
... difficulty digesting milk products may experience an increase in ... a meal replacement. //About 25% of Americans have lactose ... sufficient supply of an intestinal enzyme critical for the ... can cause such individuals to experience bloating, diarrhoea and ...
... stimulant in day to day life. According to researchers drinking ... the day progresses. During the morning hours, memory is ... For researchers at the University of Arizona have found that ... ,They had about 60-70 participants aged over 64 ...
Cached Medicine News:
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: